The role of tryptophan (TRY) and its metabolites in the pathogenesis of hepatic encephalopathy is conflicting. The aim of the present study is to investigate in posthepatitis cirrhotic patients with encephalopathy the serum levels of TRY and those of its metabolite indole-3-acetic acid, as well as TRY binding curve to serum albumin and the competition with indole-3-acetic acid. The presence of a relationship between encephalopathy severity and circulating free TRY was also investigated.
Methods
Serum TRY and indole-3-acetic acid were analyzed by HPLC; binding of TRY to serum albumin and the competition with indole-3-acetic acid was studied by equilibrium dialysis.
Results
Serum-free TRY was significantly higher in cirrhotic patients (43.33 ± 14.70 vs 28.87 ± 8.77 µmol/L, P=0.02). The binding capacity of albumin was reduced in cirrhotics and further decreased by the addition of indole-3-acetic (K=6.63 ± 0.97×10 mol/L, y=1.16 ± 0.45×10 mol/L in normal sera vs K=1.04 ± 0.20×10 mol/L, y=1.91 ± 0.92 10 mol/L in cirrhotic sera). A multivariate analysis showed that among the psychometric tests the only independent predictor of serum levels of free TRY was the Block Design (R=0.94, B=0.16 ± 0.01, β=0.97; P<0.0001).
Conclusions
A high percent ratio of free/total TRY and indoleacetic acid (IAA) was found in cirrhotic patients with hepatic encephalopathy. The concentrations of serum-free IAA and TRY correlated with the degree of subclinical encephalopathy, suggesting a role of these compounds in the development of mental derangement in liver cirrhosis.
HirayamaC.Tryptophan metabolism in liver disease. Clin Chim Acta1971;32:191–197.
2.
CurzonG, KantamaneniBD, FernandoJC, WoodsMS, CavanaghJB.Effects of chronic porto-caval anastomosis on brain tryptophan, tyrosine and 5hydroxytryptamine. J Neurochem1975;24:1065–1070.
3.
JamesJH, HodgmanJM, FunovicsJM, YoshimuraN, FischerJE.Brain tryptophan, plasma free tryptophan and distribution of plasma neutral amino acids. Metabolism1976;25:471–476.
4.
RosenHM, YoshimuraN, HodgmanJM, FischerJE.Plasma amino acid patterns in hepatic encephalopathy of differing etiology. Gastroenterology1977;72:483–487.
5.
OnoJ, HutsonDG, DombroRS, LeviJU, LivingstoneA, ZeppaR.Tryptophan and hepatic coma. Gastroenterology1978;74:196–200.
6.
BengtssonF, GageFH, JeppssonB, NobinA, RosengrenE.Brain monoamine metabolism and behavior in portacaval shunted rats. Exp Neurol1985;90:21–35.
7.
MansAM, ConsevageMW, De JospehMR, HawkinsRA.Regional brain monoamines and their metabolites after portacaval shunting. Metab Brain Dis1987;2:183–193.
8.
ReaderTA, GrondinL.Distribution of catecholamines, serotonin, and their major metabolites in the rat cingulate, piriform-entorhinal somatosensory, and visual cortex: a biochemical survey using high performance liquid chromatography. Neurochem Res1987;12:1087–1097.
9.
BasileAS, SaitoK, Al-MartiniH, RecordCO, HughesRD, HarrisonP, . The relationship between plasma and brain quinolinic acid levels and the severity of hepatic encephalopathy. Gastroenterology1995;108:818–823.
10.
BergeronM, ReaderTA, Pomier LayrarguesG, ButterworthRF.Monoamines and metabolites in autopsied brain tissue from cirrhotic patients with hepatic encephalopathy. Neurochem Res1989;14:853–859.
11.
SmithAR, Rossi-FanelliF, ZiparoV, JamesJH, ParelleBA, FischerJE.Alterations in plasma and CSF amino acids, amines and metabolites in hepatic coma. Ann Surg1978;187:343–350.
12.
Kragh-HansenU.Structure and ligand binding properties of human serum albumin. Dan Med Bull1990;37:57–84.
13.
KnellAJ, DavidsonAR, WilliamsR, KantamanemiBD, CurzonG.Dopamine and serotonin metabolism in hepatic encephalopathy. Br Med J1974;1:549–551.
14.
BertuzziA, MingroneG, GandolfiA, GrecoAV, RingoirS, VanholderR.Binding of indole-3-acetic acid to human serum albumin and competition with L-tryptophan. Clin Chim Acta1997;265:183–192.
15.
PughRNH, Murray LionIM, DawsonJL, PietronMC, WillR.Transection of the oesophagus for bleeding oesophageal varices. Br J Surg1973;60:646–649.
16.
ConnHO.Trail making and number connection test in the assessment of mental state in portal systemic encephalopathy. Dig Dis1977;22:541–550.
17.
LezakMK.A compendium of tests and assessment techniques. In: Lezak MD, ed. Neuropsychological assessment. New York: Oxford University Press; 1995.
18.
SoodGK, SarinSK, MahaptraJ, BroorSL.Comparative efficacy of psychometric tests in detection of subclinical hepatic encephalopathy in nonalcoholic cirrhotics: search for a rational approach. Am J Gastroenterol1989;84:156–159.
19.
BergnerM, BobbittRA, CartnerWB, GilsonBS.The sickness impact profile: development and final revision of a health status measure. Med Care1981;19:787–805.
Van Der RijtCCD, SchalmSW, De GrootGH, De VliegerM.Objective measurement of hepatic encephalopathy by means of automated EEG analysis. Electroenceph Clin Neurophysiol1984;57:423–426.
22.
QueroJC, HartmannIJC, MeulsteeJ, HopWCJ, SchalmSW.The diagnosis of subclinical hepatic encephalopathy in patients with cirrhosis using neuropsychological tests and automated electroencephalogram analysis. Hepatology1996;24:556–560.
23.
TestaR, RodriguezG, ArvigoF, GrassoA, GrisA, NobiliF, . Cerebral blood flow and plasma free tryptophan in cirrhotics with and without hepatic encephalopathy. Ital J Neurol Sci1989;10:415–421.
24.
VanholderR, HoefligerN, De SmetR, RingoirS.Extraction of protein bound ligands from azotemic sera: comparison of 12 deproteinization methods. Kidney Int1992;41:1707–1712.
25.
BertuzziA, FinottiE, MingroneG, GrecoAV.Sebacic acid binding to human plasma albumin. Biochem Pharmacol1993;45:697–702.
26.
MingroneG, De SmetR, GrecoAV, BertuzziA, GandolfiA, RingoirS, . Serum uremic toxins from patients with chronic renal failure displace the binding of L-tryptophan to human serum albumin. Clin Chim Acta1997;260:27–34.
27.
BertuzziA, MingroneG, GandolfiA, GrecoAV, RingoirS, VanholderR.Binding of indole-3-acetic acid to human serum albumin and competition with L-tryptophan. Clin Chim Acta1997;265:183–192.
28.
McMenamyRH, OncleyJL.The specific binding of L-tryptophan to serum albumin. J Biol Chem1958;233:1436–1447.
29.
McMenamyRH, SederRH.Thermodynamic values related to the association of L-tryptophan analogues to human serum albumin. J Biol Chem1963;238:3241–3248.
30.
StreinerDL, NormanGR.Health measurement scales. Oxford, UK: Oxford Medical Publications; 1989.
31.
BravoG, PotvinL.Estimating the reliability of continuous measures with cron bach's alpha and intraclass correlation coefficient: toward the integration of two traditions. J Clin Epidemiol1991;44:381–390.
32.
NunnalyJC.Psychometric theory. New York, NY: McGraw Hill; 1978.
33.
SchenkerS, BradyCE.Pathogenesis of hepatic encephalopathy. In: Conn HO, Bircher J, eds. Hepatic encephalopathy. East Lansing, Michigan: Medi-Ed Press; 1988:15–30.
34.
ButterworthRF.The neurobiology of hepatic encephalopathy. Semin Liver Dis1996;16:235–244.
35.
RodriguezG, TestaR, CelleG, GrisA, MarencoS, NobiliF, . Reduction of cerebral blood flow in subclinical hepatic encephalopathy and its correlation with plasma-free tryptophan. J Cereb Blood Flow Metab1987;7:768–772.
36.
HertzL, MurthyCR, LaiJC.Some metabolic effects of ammonia on astrocytes and neurons in primary culture. Neurochem Pathol1987;6:97–130.
37.
ButterworthRF, LavoieJ, GiguèreJF, LayrarguesGP, BergeronM.Cerebral GABA-ergic, and glutamatergic function in hepatic encephalopathy. Neurochem Pathol1987;6:131–144.
38.
WurtmanRJ, HeftiF, MelamedE.Precursor control of neurotransmitter synthesis. Pharmacol Rev1980;32:315–335.
39.
BiggioG, FaddaF, FanniP, TagliamonteA, GessaGL.Rapid depletion of serum tryptophan, brain tryptophan, serotonin and 5-hydroxy-indolacetic acid by a tryptophan-free diet. Life Sci1964;14:1321–1329.
40.
CascinoA, CangianoC, CalcaterraV, Rossi-FanelliF, CapocacciaL.Plasma amino acid imbalance in patients with liver disease. Am J Dig Dis1978;23:591–598.
41.
CurzonG, KantamaneniBD, WinchJ, Rojas-BuenoA, Murray-LyonIM, WilliamsR.Plasma and brain tryptophan changes in experimental acute hepatic failure. J Neurochem1973;21:137–145.
42.
LalS, AronoffA, GarelisE, SourkesTL, YoungSN, De La VegaCE.Cerebrospinal fluid homovanillic acid, 5-hydroxyindoleacetic acid, lactic acid and pH before and after probenecid in hepatic coma. Clin Neurosurg1975;77:142–154.
43.
YurdaydinC, HortnaglH, SteindlP, ZimmermannC, PiflC, SingerEA, . Increased serotoninergic and noradrenergic activity in hepatic encephalopathy in rats with thioacetamide induced acute liver failure. Hepatology1990;12:695–700.
44.
Raghavendra RaoVL, GiguereJF, Pomierre LayrarguesG, ButterworthRF.Increased activities of MAOA and MAOB in autopsied brain tissue from cirrhotic patients with hepatic encephalopathy. Brain Res1993;621:349–352.
45.
CascinoA, CangianoC, FiaccadoriF, GhinelliF, MerliM, PelosiG, . Plasma and cerebrospinal fluid amino acid patterns in hepatic encephalopathy. Dig Dis Sci1982;27:828–832.
46.
YoshidaK, HirayamaC.Clinical evaluation of serum level of tryptophan in hepatobiliary disease. Clin Chim Acta1980;101:235–240.
47.
ZoliM, MarchesiniG, CecchiniL, DondiC, BianchiFB, PisiE.Binding of tryptophan to albumin in liver cirrhosis: a reappraisal of the problem. Hepatogastroenterol1981;28:87–89.
48.
KnudsenGM, SchmidtJ, AlmdalT, PaulsonOB, VilstrupH.Passage of amino acids and glucose across the blood-brain barrier in patients with hepatic encephalopathy. Hepatology1993;17:987–992.
